Radhika Tripuraneni
Director/Board Member at TERNS PHARMACEUTICALS, INC.
Radhika Tripuraneni active positions
Companies | Position | Start | End |
---|---|---|---|
TERNS PHARMACEUTICALS, INC. | Director/Board Member | 2022-07-25 | - |
Independent Dir/Board Member | 2022-07-25 | - |
Career history of Radhika Tripuraneni
Former positions of Radhika Tripuraneni
Companies | Position | Start | End |
---|---|---|---|
PROTHENA CORPORATION PLC | Corporate Officer/Principal | 2018-11-30 | 2022-08-31 |
MYOKARDIA, INC. | Corporate Officer/Principal | 2017-01-31 | 2018-02-28 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 2011-12-31 | 2016-12-31 |
ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | 2014-12-31 |
Training of Radhika Tripuraneni
University of Missouri | Doctorate Degree |
Harvard University | Graduate Degree |
Statistics
International
United States | 7 |
Ireland | 2 |
Operational
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
PROTHENA CORPORATION PLC | Health Technology |
TERNS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Radhika Tripuraneni
- Experience